自身免疫性大疱病患者未常规预防时肺孢子菌肺炎发生率
该多中心回顾性分析纳入德国、意大利、新加坡、以色列和荷兰三级中心的801例自身免疫性大疱病患者,均未接受常规预防。仅1例发生肺孢子菌肺炎,发生率为0.1%,显著低于既往提出的3.5%预防阈值(P<.001),也低于既往报道的免疫抑制皮肤病患者1.3%的发生率(P=.004)。
要点
- 自身免疫性大疱病患者PCP发生率仅0.1%,常规预防似无必要。
- 0.1%显著低于3.5%的预防阈值及免疫抑制皮肤病患者1.3%的既往发生率。
- 预防药物可能带来高钾血症、低血糖、光敏、血小板减少等风险。
核心结论
- 自身免疫性大疱病患者常规肺孢子菌预防似乎并不必要。
- 该类患者PCP风险似乎低于一般免疫抑制皮肤病患者的既往报告水平。
研究设计与样本
- 多中心回顾性病历分析,中心位于德国、意大利、新加坡、以色列和荷兰的三级诊疗机构。
- 共纳入801例确诊自身免疫性大疱病患者,平均(SD)年龄66.5(17.6)岁,女性465例(58%)。
主要发现
- 仅1例发生PCP,发生率为0.1%。
- 0.1%显著低于3.5%的推荐阈值(χ21=27.0;P<.001)。
- 0.1%显著低于既往报道的免疫抑制皮肤病患者PCP发生率1.3%(χ21=8.2;P=.004)。
关键数值与推荐
- PCP定义为ICD-9编码136.3,或依据特征性影像学表现伴乳酸脱氢酶升高进行自由文本记录,或因肺炎住院且支气管肺泡灌洗确认染色显示耶氏肺孢子菌。
- 既往曾提出至少3.5%的发生率作为支持预防的界值。
临床怎么用
- 对自身免疫性大疱病患者可不常规进行肺孢子菌预防,应结合个体风险权衡。
- 若考虑预防,需注意复方磺胺甲噁唑及阿托伐醌、氨苯砜、喷他脒等二线药物的不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pneumocystis pneumonia (PCP) is a potentially lethal opportunistic infection that primary prophylaxis can help prevent. The risk of prophylactic therapy must be weighed against the incidence of PCP in the patient population. Prophylaxis most frequently involves trimethoprim-sulfamethoxazole, with second-line therapies, including atovaquone, dapsone, and pentamide. The indication for prophylaxis in immunocompromised patients without HIV is less well defined. Previously, an incidence of at least 3.5% has been proposed as a cutoff to justify prophylaxis. OBJECTIVE: To assess the incidence of PCP in patients with autoimmune blistering diseases receiving no routine prophylaxis. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective analysis of patient medical records to determine the incidence of PCP infections. The multicenter study was performed at tertiary care centers that provide care for patients with autoimmune blistering disease in Germany, Italy, Singapore, Israel, and the Netherlands. Patients had a confirmed diagnosis of pemphigus vulgaris/foliaceus, bullous pemphigoid, epidermolysis bullosa acquisita, mucous membrane pemphigoid/cicatricial pemphigoid, or anti-p200 pemphigoid. MAIN OUTCOMES AND MEASURES: To determine the incidence of PCP defined as patients with the International Classification of Diseases, Ninth Revision (ICD-9), code 136.3, for PCP, or free text documentation of PCP occurring based on characteristic radiographic findings with elevated lactate dehydrogenase, or hospitalization for pneumonia with bronchioalveolar lavage demonstrating Pneumocystis jiroveci on confirmatory stains. RESULTS: A total of 801 patients with autoimmune blistering diseases were included in this study; their mean (SD) age was 66.5 (17.6) years, and a total of 465 (58%) were female. Only 1 patient developed PCP, resulting in an incidence rate of 0.1%. This incidence significantly fell below the recommended threshold of 3.5% (0.1% vs 3.5%, χ21 = 27.0; P < .001). This incidence was significantly lower than the previously reported incidence of PCP in all immunosuppressed dermatologic patients (0.1% vs 1.3%; χ21 = 8.2; P = .004). CONCLUSIONS AND RELEVANCE: Routine Pneumocystis prophylaxis for patients with autoimmune blistering diseases does not seem to be warranted. Patients with autoimmune blistering disease seem to have a lower risk of PCP than the general population of immunosuppressed dermatology patients. Risks of routine prophylaxis include hyperkalemia, hypoglycemia, photosensitivity, thrombocytopenia, and more rare adverse reactions.
引用
- Amber KT, Lamberts A, Solimani F, et al. Determining the Incidence of Pneumocystis Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis. JAMA Dermatol. 2017. PMID: 28854309. doi:10.1001/jamadermatol.2017.2808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。